| Current and future therapeutic approaches for osteosarcoma |
110 |
| Role of chemotherapy and targeted therapy in early-stage non-small cell lung cancer |
22 |
| Nivolumab for the treatment of hepatocellular carcinoma |
18 |
| Targeted therapies in non-small cell lung cancer: a focus on ALK/ROS1 tyrosine kinase inhibitors |
17 |
| A comprehensive review of protein kinase inhibitors for cancer therapy |
15 |
| Current research into novel therapeutic vaccines against cervical cancer |
12 |
| The eighth edition American Joint Committee on Cancer (AJCC) melanoma staging system: implications for melanoma treatment and care |
12 |
| Challenges and concerns of persistent opioid use in cancer patients |
12 |
| Targeted therapy for metastatic colorectal cancer |
11 |
| Managing side effects in adjuvant endocrine therapy for breast cancer |
11 |
| Difference between right-sided and left-sided colorectal cancers: from embryology to molecular subtype |
11 |
| Current and future immunotherapies for thyroid cancer |
11 |
| Capmatinib for the treatment of non-small cell lung cancer |
11 |
| Combination therapies for the treatment of HER2-positive breast cancer: current and future prospects |
11 |
| Current and future therapeutic approaches for the treatment of small cell lung cancer |
10 |
| Larotrectinib for the treatment of TRK fusion solid tumors |
10 |
| Mathematical models of tumor cell proliferation: A review of the literature |
10 |
| Future applications of FGF/FGFR inhibitors in cancer |
10 |
| Decision-making for adrenocortical carcinoma: surgical, systemic, and endocrine management options |
9 |
| Imaging of pancreatic neuroendocrine tumors: recent advances, current status, and controversies |
9 |
| Optimizing treatments for recurrent or metastatic head and neck squamous cell carcinoma |
9 |
| The landscape of tyrosine kinase inhibitors in sarcomas: looking beyond pazopanib |
9 |
| Immune checkpoint-based therapy in myeloid malignancies: a promise yet to be fulfilled |
9 |
| The diagnosis and management of extramammary Paget's disease |
9 |
| The role of tumor angiogenesis as a therapeutic target in colorectal cancer |
9 |
| Personalizing surgical margins in retroperitoneal sarcomas: an update |
8 |
| The role of combination chemo-immunotherapy in advanced non-small cell lung cancer |
8 |
| Initiatives to reduce postoperative surgical site infections of the head and neck cancer surgery with a special emphasis on developing countries |
8 |
| Role of omega-3 polyunsaturated fatty acids in preventing gastrointestinal cancers: current status and future perspectives |
8 |
| Therapeutic approaches for refractory germ cell cancer |
8 |
| Liquid biopsies in gastrointestinal malignancies: when is the big day? |
8 |
| Epidermal growth factor receptor tyrosine kinase inhibitors for the treatment of non-small cell lung cancer |
8 |
| Management Strategies for Recurrent Endometrial Cancer |
8 |
| Apalutamide for the treatment of prostate cancer |
7 |
| Sorafenib: key lessons from over 10 years of experience |
7 |
| The prognostic role of circulating tumor cells in colorectal cancer |
7 |
| Management of immune-related adverse events resulting from immune checkpoint blockade |
7 |
| Anti-BCMA antibodies in the future management of multiple myeloma |
7 |
| The development of fluorescence guided surgery for pancreatic cancer: from bench to clinic |
7 |
| An update on radiation therapy in head and neck cancers |
6 |
| Peritoneal dissemination of ovarian cancer: role of MUC16-mesothelin interaction and implications for treatment |
6 |
| Surgical management of spinal metastases |
6 |
| Adjuvant therapy for advanced renal cell carcinoma |
6 |
| The role of circulating free DNA in the management of NSCLC |
6 |
| Olaparib for the treatment of breast cancer |
6 |
| Tisagenlecleucel for the treatment of B-cell acute lymphoblastic leukemia |
6 |
| Lenvatinib as a therapy for unresectable hepatocellular carcinoma |
6 |
| Oral and Oropharyngeal squamous cell carcinoma: prognostic and predictive parameters in the etiopathogenetic route |
6 |
| The role of prostate cancer antigen 3 (PCA3) in prostate cancer detection |
5 |
| Remodeling the cancer epigenome: mutations in the SWI/SNF complex offer new therapeutic opportunities |
5 |
